Highlights Nuvalent, Inc.

Equities

NUVL

US6707031075

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
68.88 ^USD	+1.37%		+1.89%	-6.40%

Apr. 17	Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing	MT
Apr. 17	Jefferies Initiates Nuvalent With Buy Rating, $97 Price Target	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Nuvalent, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Nuvalent, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Nuvalent, Inc. Initiates the Phase 2 Portion of Alkove-1 Clinical Trial for Patients with Alk-Positive Nsclc and Other Solid Tumors	Feb. 12	CI
Nuvalent, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Nuvalent, Inc. Announces Preliminary Data from the Phase 1 Dose-Escalation Portion of Its Ongoing ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer and Other Solid Tumors	23-10-04	CI
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium	23-09-18	CI
Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with Ros1-Positive NSCLC and Other Solid Tumors	23-09-05	CI
Nuvalent's Q2 Net Loss Widens	23-08-10	MT
Nuvalent, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Nuvalent, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Nuvalent, Inc. Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023	23-04-18	CI
Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)	23-03-23	CI
Nuvalent's Q4 Net Loss Widens; Company Expects Cash Position to Provide Runway Into Second Half of 2025	23-03-16	MT
NUVALENT, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-16	AQ
Nuvalent, Inc. to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023	23-03-14	CI
Nuvalent Inc. Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520	22-12-13	CI
NUVALENT, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-10	AQ
Nuvalent, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Nuvalent Q3 Net Loss Widens	22-11-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Nuvalent, Inc.

Equities

NUVL

US6707031075

Highlights

Filters